Last checked at 26 Jul 2022 11:22
IXICO plc
("IXICO" or the "Company")
This announcement replaces RNS number 2135T released on 21 July 2022 at 07.00.
Contract win for a Phase 2 Huntington's disease trial worth circa £2.1m
IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it has been selected by a leading global pharma company to support their drug development programme in Huntington's disease ('HD'). HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities, leading to irreversible decline and eventual death.
Across previous HD trials, IXICO has deployed radiology services and advanced MRI techniques to enable patient eligibility and safety monitoring and to improve understanding of the pharmacodynamic aspects of the treatment. This understanding is now supporting the design, planning and implementation of further clinical research.
Having built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders since its inception in 2004, IXICO continues to develop its extensive portfolio of advanced neuroimaging solutions and services across the entire drug development lifecycle, from Phase I through to commercialisation.
Giulio Cerroni, CEO of IXICO, commented: "We are delighted to continue our partnership with one of the world's leading pharmaceutical companies working in the field of neurodegenerative diseases."
For further information please contact:
IXICO plc | +44 (0)20 3763 7499 | |
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |
| ||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |
Giles Balleny / Max Gould (Corporate Finance) | ||
Michael F Johnson / Tamar Cranford-Smith (Sales) | ||
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews